Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Bone neoplasms are abnormal growths in bone tissue that may be benign or malignant, with osteosarcoma, chondrosarcoma, and Ewing sarcoma among the major primary types. In the United States, approximately 4,110 new bone and joint cancer cases are projected for 2026, representing about 0.2% of all new cancer cases. Current bone neoplasm treatment commonly involves surgery, chemotherapy, and radiation, depending on tumor type and stage. According to the bone neoplasms pipeline analysis by Expert Market Research, growing R&D activity, unmet treatment needs, and advances in targeted, biologic, and immunotherapeutic approaches are supporting a broader drug pipeline. Continued clinical development is expected to strengthen therapeutic options in the coming years.
-
Major companies involved in the bone neoplasms pipeline analysis include Amgen, Emerald Clinical Inc., and others.
-
Leading drugs currently in the pipeline include XGEVA, OST31-164, 153Sm-DOTMP, and others.
-
Targeted antibody-drug conjugates, immunotherapies, and radioligand therapies are strengthening clinical development, while biomarker-driven approaches and combination regimens expand treatment options for relapsed and refractory disease.
Report Coverage
The Bone Neoplasms Pipeline Analysis Report by Expert Market Research gives comprehensive insights into bone neoplasms therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for bone neoplasms. The bone neoplasms report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The bone neoplasms pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with Bone Neoplasms treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to bone neoplasms.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Bone Neoplasms Pipeline Outlook
Bone neoplasms are abnormal growths of cells that develop within bone tissue and may be benign or malignant. They occur when genetic changes disrupt normal cell growth and division, leading to uncontrolled cell proliferation. Malignant tumors can invade surrounding bones and tissues or spread to distant organs, resulting in primary or metastatic bone cancer.
Bone neoplasms are treated based on tumor type, stage, location, and aggressiveness. Treatment options include surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy, and supportive medicines that help manage bone complications and reduce skeletal-related events. In September 2025, the U.S. Food and Drug Administration approved Bildyos (denosumab-nxxp) and Bilprevda (denosumab-nxxp) as biosimilars to Prolia and Xgeva. Bilprevda is indicated to prevent skeletal events associated with bone metastases and multiple myeloma, expanding bone cancer treatment options.
Bone Neoplasms Epidemiology
The pipeline is supported by the continued need for improved treatment options for rare bone cancers. According to The University of Texas, more than 3,200 people in the United States are diagnosed annually with primary cancer of the bones and joints, representing 0.2% of all cancers. As per Özel Doç. Dr. Özgür Erdoğan, approximately 550 people in the United Kingdom are diagnosed with bone tumors each year, equivalent to 8 cases per 1 million people. These epidemiological trends highlight the need for continued bone cancer drug development and pipeline innovation.
Bone Neoplasms – Pipeline Therapeutic Assessment
This section of the report covers the analysis of bone neoplasms drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase 1)
- Preclinical and Discovery Stage Products
By Drug Class
The bone neoplasms pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Cell Therapies
- Peptides
- Antibody-Drug Conjugates
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
- Oral
- Parenteral
- Others
Bone Neoplasms Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to Expert Market Research's analysis, phase II covers a major share of the total bone neoplasms clinical trials. Phase II accounts for 49%, supported by the largest development base and strong potential to advance treatment options. Phase I follows with 37%, strengthening innovation and expanding the future treatment pipeline. Phase III represents 10%, providing promising late-stage opportunities. Early phase I and phase IV together contribute 4%, supporting continued development and post-approval evidence generation.
Bone Neoplasms Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the bone neoplasms pipeline analysis include small molecules, monoclonal antibodies, cell therapies, peptides, and antibody-drug conjugates. The bone neoplasms report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for bone neoplasms. Antibody-drug conjugates are emerging as a targeted treatment approach in the bone neoplasms market drug pipeline. For instance, GSK and Hansoh Pharmaceutical’s ris-rez (HS-20093) is an antibody-drug conjugate being evaluated for relapsed osteosarcoma. GSK and Hansoh Pharmaceutical’s ris-rez (HS-20093), an antibody-drug conjugate, met the primary endpoint of progression-free survival in a late-stage trial for relapsed osteosarcoma. This development highlights the potential of targeted therapies for bone cancer and supports continued clinical development of ADC-based treatments for osteosarcoma.
Bone Neoplasms Clinical Trials – Key Players
The EMR report for the bone neoplasms pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed bone neoplasms therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in bone neoplasms clinical trials:
- Amgen
- Emerald Clinical Inc.
- Telix Pharmaceuticals (Innovations) Pty Limited
- Shanghai JMT-Bio Inc.
- Incyte Corporation
- Eli Lilly and Company
- Novartis Pharmaceuticals
- Jubilant Therapeutics Inc.
- AbbVie
- Jazz Pharmaceuticals
- Bristol-Myers Squibb
Bone Neoplasms – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for bone neoplasms. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of bone neoplasms drug candidates.
Drug: XGEVA
XGEVA® (denosumab), sponsored by Amgen, is being evaluated in a Phase 4, open-label, multicenter study involving Chinese adults and skeletally mature adolescents with giant cell tumor of bone (GCTB). The study is examining the efficacy of XGEVA® in 36 participants. Denosumab is a monoclonal antibody that binds to RANKL, blocking osteoclast formation and activity and reducing bone breakdown. By inhibiting RANKL signaling, the drug is preventing GCTB cells from growing and damaging bone, allowing normal bone to replace the tumor. The study is scheduled for completion on March 7, 2028.
Drug: OST31-164
OST31-164, sponsored by Emerald Clinical Inc., is being evaluated as a maintenance therapy for patients aged 12–39 with recurrent osteosarcoma that has been surgically removed from the lungs. The Phase 2 study is examining whether OST31-164 will support disease control following resection. The drug is being administered as a single-agent intravenous infusion at 1×10⁹ CFU every three weeks for 48 weeks, with four doses forming each 12-week cycle. OST31-164 contains HER2-derived epitopes designed to stimulate immune responses. The study is estimated to be completed by October 2027, followed by a three-year survival follow-up.
Drug: 153Sm-DOTMP
TLX090-Tx (153Sm-DOTMP), sponsored by Telix Pharmaceuticals (Innovations) Pty Limited, is being evaluated in a Phase 1 study for patients with painful bone metastases. This clinical-stage, bone-seeking targeted radiopharmaceutical is using Samarium-153 with a next-generation chelating agent to selectively target bone. The study is examining its safety, pharmacokinetics, radiation dosimetry, dose optimization, and preliminary efficacy following a single dose. The open-label, two-part study will enroll an estimated 33 participants, with primary completion expected on April 26, 2027, and overall study completion expected on July 5, 2027.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Bone Neoplasms Pipeline Insight Report
- Which companies/institutions are leading the bone neoplasms drug development?
- Which company is leading the bone neoplasms pipeline development activities?
- What is the current bone neoplasms commercial assessment?
- What are the opportunities and challenges present in the bone neoplasms pipeline landscape?
- What is the efficacy and safety profile of bone neoplasms pipeline drugs?
- Which company is conducting major trials for bone neoplasms drugs?
- Which companies/institutions are involved in bone neoplasms collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in Bone Neoplasms?
Reasons To Buy This Report
The bone neoplasms pipeline analysis report provides a strategic overview of the latest and future landscape of treatments for bone neoplasms. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into Bone Neoplasms collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
